深圳能源(000027.SZ):擬33.53億元投建新疆疏勒縣200萬千瓦光儲一體化項目一期工程
格隆匯11月28日丨深圳能源(000027.SZ)公佈,公司全資子公司深能北方能源控股有限公司(簡稱“北方控股公司”)的全資子公司深能疏勒新能源開發有限公司(簡稱“深能疏勒新能源公司”)擬投資建設新疆疏勒縣200萬千瓦光儲一體化項目一期工程(50萬千瓦)。
該項目總投資約為33.53億元,其中自有資金約為6.73億元,其餘投資款擬通過融資解決,考慮到北方控股公司資金情況,該次擬由公司為上述項目向北方控股公司增資約6.73億元,北方控股公司為上述項目向深能疏勒新能源公司增資約6.71億元,增資後深能疏勒新能源公司的註冊資本由200萬元增至約6.73億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.